View Article Online View Journal

NJC Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: R. Sharma, F. A. Sofi, P. Rana and Prasad. V. Bharatam, *New J. Chem.*, 2019, DOI: 10.1039/C8NJ05504A.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the **author guidelines**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the ethical guidelines, outlined in our <u>author and reviewer resource centre</u>, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.



rsc.li/njc

5 6 7

12 13

14

15

9 4:37:41.AM

Tulare Weiversity on 2,828,9.

<u>2</u>8

lishedon 09 February 2019 Drwn loaded

940 41 42

43

44 45 46

47

48 49

50

51

52

53

54

55

56

57

58

59

60

Journal Name



Bimetallic Cu-Mn B spinel oxide catalyzed oxidative synthesis of 1,2-disubstituted benzimidazoles from benzyl bromides

Received 00th January 20xx, Accepted 00th January 20xx

Rohit Sharma,^{a#} Firdoos Ahmad Sofi,^{a#} Preeti Rana,^a Prasad V. Bharatam^{a*}

DOI: 10.1039/x0xx00000x

www.rsc.org/

Cu-Mn B, (a heterogeneous catalyst) catalyzed synthesis of 1benzyl-2-phenyl-1H-benzo[d]imidazolesis reported. In this reaction, 2-phenyl-1H-benzo[d]imidazoles are found to be the side products. Reported protocol is simple, highly efficient, tolerates wide variety of substrates and products were formed in good to excellent yield.

The 1,2-disubstituted benzimidazoles are privileged scaffold present in various natural and medicinally important compounds. This type of scaffold is also present in various types of marketed drugs as well.¹⁻⁴ These are one of the most important *N*-heterocycles in terms of drug discovery perspective.⁵⁻⁷ The therapeutic application of these compounds are reported in hypertension,⁸ obesity,⁹ HIV,⁷ HSV-1¹⁰ and influenza.¹¹ Thus, the development of efficient methods for the synthesis of 1,2-disubstituted benzimidazole scaffold is of utmost importance in organic synthesis.



Figure 1. Previous methods and our approach.

Various methods were reported in literature for the synthesis of benzimidazole scaffold, ¹²⁻¹⁴ but only a few methods were reported for the synthesis of 1,2-disubstituted benzimidazoles, these include

condensation of o-phenylenediamine with aldehyde,¹⁵ C-H N,N⁻-diphenyl formamidine,¹⁶ coupling amination reaction of reaction between N-benzyl-2-iodoaniline and benzamide,¹⁷ reaction of 2-nitroaniline with benzyl bromide and aldehyde¹⁸ and acceptorless dehydrogenative coupling of tertiary amines and arylamines.¹⁹ But, all these reported methods suffer from various drawbacks, such as the use of harsh reaction conditions, low substrate scope, lower yields and longer reaction times. Based on these reports, we started working towards the synthesis of 1,2disubsituted benzimidazoles by using bimetallic Cu-Mn catalyst available with us. Cu-Mn B catalyst is prepared by using literature reported method.²⁰ This catalyst has been used in various organic transformations which involves Chan-Lam type of coupling reaction for C-N bond formation,²¹ Husigen cyclo addition reaction, regioselective halogenations of phenols and N-heterocycles,²² synthesis of imidazopyridine scaffold,²³ synthesis of amides²⁴ and in nitrogen insertion reaction for the synthesis of quinazolinones.²⁵ Inspired from previous literature reports and our ongoing interest for the synthesis of *N*-heterocycles,^{24, 25} we started working towards exploring catalytic application of Cu-Mn spinel oxide for the synthesis of N-heterocycles.



Figure 2. Cu-Mn B catalyzed synthesis of 1-benzyl-2-phenyl-1H-benzo[d]imidazole and 2-phenyl-1H-benzo[d]imidazole.

Initial attempt was to utilize Cu-Mn B catalyst for the synthesis of 1-benzyl-2-phenyl-1H-benzo[d]imidazole. After getting insight from literature for the synthesis of 1-benzyl-2-phenyl-1H-benzo[d]imidazole, it was found suitable to utilize *o*-Phenylenediamine and benzyl bromide as starting material. Firstly, model reaction was conducted using Cu-Mn B as catalyst, in the presence of ligand L-proline, DMSO and K_2CO_3 under reflux conditions for 12 h, but we were able to isolate desired product in 25 % yield with the formation of 2-phenyl-1H-benzo[d]imidazole **4a** as well in 40 % yield. Further reaction was conducted without using

^{a.} Department of Medicinal Chemistry, National Institute of Pharmaceutical

Education and Research. S.A.S Nagar-Mohali-160062

[#] These authors contributed equally

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

COMMUNICATION

1 2

View Article Online

DOI: 10.1039/C8NJ05504A

60

ligand. To our surprise, the desired product **3a** was formed in 68 % yield and 2-phenyl-1H-benzo[d]imidazole **4a** was formed in 20 %.

Table 1. Solvent and catalyst optimization studies^a

1a



2a



Entrv	Catalyst(% (w/w)	Temp. (º	C) Base(equiv)	Time (h)	Solvent	Ligand(equiv)	%Yield ^a (3a/4a)
1.	CuCl ₂ (10)	110	K ₂ CO ₃ (3)	12	DMSO	None	0
2.	CuCl ₂ (10)	110	K_2CO_3 (3)	12	DMSO	L-proline (20)	0
3.	CuO (10)	110	K_2CO_3 (3)	12	DMSO	None	Trace
4.	$Cu(OAc)_2(10)$	110	K_2CO_3 (3)	12	DMSO	None	(15:40)
5. ^b	Cu-Mn B (10)	110	K_2CO_3 (3)	12	DMSO	None	(68:20)
6	Cu-Mn B (20)	110	K_2CO_3 (3)	12	DMSO	None	66:18
7.	Cu-Mn B (10)	110	K_2CO_3 (3)	12	DMSO	L-proline (20)	(25:40)
8.	CuO (10)	110	K ₃ PO ₄ (3)	12	DMSO	None	trace
9.	Cu(OTf) ₂	110	K_2CO_3 (3)	12	DMSO	None	0
10. ^c	Cu-Mn B (10)	110	K ₂ CO ₃ (3)	12	DMSO	None	50:10
11. ^c	Cu-Mn B (10)	110	K ₂ CO ₃ (3)	12	Toluene	None	0:50
12. ^d	Cu-Mn B (10)	110	K ₂ CO ₃ (3)	12	DMSO	None	50:50
13	Cu-Mn B (10)	90	K ₂ CO ₃ (3)	12	Water	None	0:10
14.	Cu-Mn B (10)	110	K ₂ CO ₃ (3)	12	DMF	None	10:40

Reagents and conditions: *o*-phenylenediamine **1a** (1 equiv.), benzyl bromide **2a** (2 equiv.), Cu-Mn B (10% w/w), K_2CO_3 (2.5 equiv.), DMSO (3mL); ^{*a*} isolated yield; ^{*b*} optimized reaction condition; ^{*c*} under N_2 atmosphere; ^{*d*} under O_2 atmosphere

The separation of the two products in column chromatography has been found to be easy because of their distinguishable R_f values. In this reaction selectivity for 3a was achieved by 77 %. Further screening of the catalytic reaction was done by using various solvents such as toluene, DMF and water but none of them found to be efficient for this transformation. We also tried Cu (I) and Cu (II) catalyst for this transformation but none of them found suitable. Cu-Mn B was found to be suitable catalyst for this transformation. This might be due to distinct Cu-Mn B phase as shown in previous literature reports based on PXRD.²⁴ Also, in case of Cu-Mn B, as revealed in XPS analysis, these metals exit in multiple oxidation states (Cu⁺², Mn^{+2} , Mn^{+3} and Mn^{+4}) in bimetallic Cu-Mn catalyst. Having optimized reaction conditions in hand, next we tried to explore substrate scope of reaction for various substituted benzyl bromides, reaction works well with all substituted benzyl bromides bearing electron withdrawing (Figure 3 entry, 3d, 3e and 3f) as well as electron donating group (Figure 3 entry, 3b, 3c and 3g)

Yields in case of electron withdrawing groups (Figure 3 entry **3d**, **3e** and **3f**) in benzyl bromides are slightly higher in comparison to electron donating groups (Figure 3 entry, **3b**, **3c** and **3g**). Also, we tried various substituted OPDs (*o*-Phenylenediamine) bearing electron withdrawing (Figure 3 entry **3h**, **3i**, **3j**, **3k** and **3p**) and electron donating groups (Figure 3 entry **3l**, **3m** and **3n**) as well as di-substituted OPDs (Figure 3 entry **3o** and **3p**).

Apart from that, strong electron withdrawing group, such as 5nitro OPD (Figure 3 entry, **3h** and **3i**) was also tried in this reaction. The reaction works well with all types of substituted OPDs giving corresponding product in good yields. In case of electron withdrawing groups in OPDs (Figure 3 entry **3h**, **3i**, **3j**, **3k** and **3p**), yields are lesser in comparison in electron donating groups (Figure 4 entry **3l**, **3m** and **3n**).

Benzyl bromide bearing substituents in *meta* position (Figure 3, entry **3c**, **3f** and **3i**) gave slightly lower yield in comparison to *para* substituents (Figure 3, entry **3b**, **3d**, **3e**, **3g**, **3k**, **3n** and **3o**). Also, in case of OPD bearing disubstituted 4,5-dichlorobenzene-1,2-diamine (Figure 3 entry **3p**) reaction works well giving corresponding product in good yield. No particular electronic effect was seen in the synthesis of 2-aryl benzimidazole.

9 4:37:41.AM

<u></u>28

ished on U9 Eebraary 2019 Downloaded



Reagents and conditions: OPD **1a** (1 equiv.), benzyl bromide **2a** (2 equiv.), Cu-Mn B (10 %w/w), K₂CO₃ (3 equiv.), DMSO (3 mL), 110 °C, 12 h **Figure 3.** Substrate scope of reaction by using substituted OPD and benzyl bromides.

A plausible mechanism of reaction can be proposed (Figure 4), which involves initial Ullmann type of coupling between OPD and benzyl bromide leading to the formation of the doubly *N*-alkylated intermediate I. Oxidation of benzylic carbon in intermediate I leads to the generation of iminic intermediate II. Subsequently, cyclization happens due to the nucleophilic attack of benzylic nitrogen at the iminic carbon centre, leading to the formation of intermediate III. Additional oxidation step leads to the formation of final product **3a**. Mono substituted benzimidazole, intermediate IV also may be formed in the initial step, yielding 2-aryl benzimidazole

4a along a similar pathway. Formation of compound **3a** from the preformed **4a** is also possible in the same catalytic condition as evidenced by the control experiment.

This journal is © The Royal Society of Chemistry 20xx



Figure 4: Plausible mechanism for the generation of title compounds

COMMUNICATION



267 nm 274 nm 274 nm 274 nm 274 nm 274 nm 200 k SE 10/22/2018

(a)

(b) Figure 5: SEM analysis images before (a) and after use (b).

Next, we tried to check the recyclability of catalyst. The catalyst was recovered by filtration after every reaction and reused for four successive reactions for the synthesis of 2-Aryl-*N* benzyl benzimidazole **3a** without loss of significant activity. The % yields over 4 cycles were 68, 65, 60 and 55 %. The reduction in the yields during recycling process may be attributed to the limitations in the catalyst recovery. Further, in order to know the surface morphology of catalyst and size of Cu-Mn B nanoparticles, Scanning electron microscopy analysis shows that surface morphology of the catalyst remains same before and after four cycles of reaction also size of nanoparticles remains same.

In summary, we have developed an efficient method for the synthesis of 1,2-disubstituted benzimidazoles using bimetallic catalyst in one pot. Further, reaction has wide substrate scope, various functional groups are well tolerated and catalyst can be reused up to four cycles. The side product 2-aryl benzimidazole also can be isolated, though in small yields.

Acknowledgements

The authors thank Mrs. Parveen Sharma from CSIR-IIIM, Jammu for technical support. RS thanks to DST-SERB, New Delhi for the award of Postdoctoral research fellowship (file no. PDF/2017/000232).

Notes and references

- 1. M. Sharpe, B. Jarvis and K. L. Goa, *Drugs*, 2001, 61, 1501-1529.
- J. L. Falcó, M. Piqué, M. González, I. Buira, E. Méndez, J. Terencio, C. Pérez, M. Príncep, A. Palomer and A. Guglietta, *Eur. J. Med. Chem.*, 2006, 41, 985-990.
- T. Ishida, T. Suzuki, S. Hirashima, K. Mizutani, A. Yoshida, I. Ando, S. Ikeda, T. Adachi and H. Hashimoto, *Bioorg. Med. Chem. Lett.*, 2006, 16, 1859-1863.
 - S. Hirashima, T. Suzuki, T. Ishida, S. Noji, S. Yata, I. Ando, M. Komatsu, S. Ikeda and H. Hashimoto, *J. Med. Chem.*, 2006, 49, 4721-4736.

4.

COMMUNICATION

1	
2	
3	
Δ	
-	
S	
6	
7	
8	
9	
1	^
	0
1	1
1	2
1	3
1.	4
1	5
1	ر م
Ž	6
4	7
Ę	8
4:3	9
6	ĥ
20	1
8	I
7	2
2	3
B.	4
ē.	5
3	2
aRe	6
2	7
2	8
3	9
bag	n
-Jux	1
ð	1
3	2
3	3
3	4
D an	5
[eb	ر د
P 6	0
S	/
3	8
ş	9
-94	n
P	1
4	1
4	2
4	3
4	4
4	5
1	6
4	2
4	/
4	8
4	9
5	0

Journal Name

- 5. S. Braun, A. Botzki, S. Salmen, C. Textor, G. Bernhardt, S. Dove and A. Buschauer, *Eur. J. Med. Chem.*, 2011, 46, 4419-4429.
- T. W. Moore, K. Sana, D. Yan, S. A. Krumm, P. Thepchatri,
 J. P. Snyder, J. Marengo, R. F. Arrendale, A. J. Prussia, M.
 G. Natchus, D. C. Liotta, R. K. Plemper and A. Sun, ACS
 Med. Chem. Lett., 2013, 4, 762-767.

7. A. R. Porcari, R. V. Devivar, L. S. Kucera, J. C. Drach and L.

- B. Townsend, J. Med. Chem., 1998, 41, 1252-1262.
- 1 8. S. Vasiliou, *Drugs Today*, 2011, 47, 647-651.
- 29.P. H. O. A. K. Petersen, L. B. Christiansen, H. C. Hansen and3F. E. Nielsen, High Point Pharmaceuticals, 2008, US47915299 B7915292.
- M. T. Migawa, J.-L. Girardet, J. A. Walker, G. W. Koszalka,
 S. D. Chamberlain, J. C. Drach and L. B. Townsend, *J. Med. Chem.*, 1998, 41, 1242-1251.
 - 11. I. Tamm, Science, 1957, 126, 1235-1236.
 - 12. P. N. Preston, *Chem. Rev.*, 1974, 74, 279-314.
 - 13. L. B. Townsend and G. R. Revankar, *Chem. Rev.*, 1970, 70, 389-438.
 - 14. D. Xue and Y.-Q. Long, J. Org. Chem., 2014, 79, 4727-4734.
 - 15. H. Sharma, N. Kaur, N. Singh and D. O. Jang, *Green Chem.*, 25. 2015, 17, 4263-4270.

- 16. R. K. Kumar and T. Punniyamurthy, *RSC* Adv. 2012 4616-4619. DOI: 10.1039/C8NJ05504A
- 17. C. Xie, X. Han, J. Gong, D. Li and C. Ma, *Org. Biomol. Chem.*, 2017, 15, 5811-5819.
- 18. D. N. Kommi, P. S. Jadhavar, D. Kumar and A. K. Chakraborti, *Green Chem.*, 2013, 15, 798-810.
- 19. X. Sun, X.-H. Lv, L.-M. Ye, Y. Hu, Y.-Y. Chen, X.-J. Zhang and M. Yan, *Org. Biomol. Chem.*, 2015, 13, 7381-7383.
- 20. S. K. Yousuf, D. Mukherjee, B. Singh, S. Maity and S. C. Taneja, *Green. Chem.*, 2010, 12, 1568-1572.
- S. D. Sawant, M. Srinivas, K. A. A. Kumar, G. L. Reddy, P. P. Singh, B. Singh, A. K. Sharma, P. R. Sharma and R. A. Vishwakarma, *Tetrahedron Lett.*, 2013, 54, 5351-5354.
- P. P. Singh, T. Thatikonda, K. A. Kumar, S. D. Sawant, B. Singh, A. K. Sharma, P. R. Sharma, D. Singh and R. A. Vishwakarma, *J. Org. Chem.*, 2012, 77, 5823-5828.
- J. B. Bharate, S. K. Guru, S. K. Jain, S. Meena, P. P. Singh, S. Bhushan, B. Singh, S. B. Bharate and R. A. Vishwakarma, *RSC Adv.*, 2013, 3, 20869-20876.
- 24. R. Sharma, R. A. Vishwakarma and S. B. Bharate, *Adv. Synth. Catal.*, 2016, 358, 3027-3033.
 - R. Sharma, R. A. Vishwakarma and S. B. Bharate, *Eur. J. Org. Chem.*, 2016, 2016, 5227-5233.

Vew Journal of Chemistry Accepted M